Zyflo CR

See also: Generic Zyflo

Zyflo CR is a brand name of zileuton, approved by the FDA in the following formulation(s):

ZYFLO CR (zileuton - tablet, extended release; oral)

• 
  Manufacturer: CORNERSTONE THERAP
  
  Approval date: May 30, 2007
  
  Strength(s): 600MG ^[RLD]

Has a generic version of Zyflo CR been approved?

No. There is currently no therapeutically equivalent version of Zyflo CR available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyflo CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tablets with controlled-rate release of active substances
  Patent 5,422,123
  Issued: June 6, 1995
  Inventor(s): Conte; Ubaldo & La Manna; Aldo & Colombo; Paolo
  Assignee(s): Jagotec AG
  Tablets with zero order controlled-rate of release of the active substances, consisting of a core of defined geometrical form containing the active substance, polymer substances which swell on contact with aqueous liquids and polymer substances with gelling properties, and a support applied to said core to partly cover its surface, the support consisting of polymer substances which are slowly soluble and/or slowly gellable in aqueous liquids, plasticizing substances, and possibly substances with an adjuvant function.
  
  Patent expiration dates:
  
  
  • June 6, 2012
    
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical tablet capable of liberating one or more drugs at different release rates
  Patent 6,183,778
  Issued: February 6, 2001
  Inventor(s): Conte; Ubaldo & LaManna; Aldo & Maggi; Lauretta
  Assignee(s): Jagotec AG
  Pharmaceutical tablet consisting of a first layer containing one or more drugs with immediate or controlled release formulation, a second layer containing one or more drugs, either equal to or different from the first layer, with slow release formulation, and a low-permeability barrier-type layer coating said second layer or, alternatively, placed between the first and second layer and, if necessary, containing a drug.
  
  Patent expiration dates:
  
  
  • September 21, 2013
    
    ✓ 
    Drug product
  
  

See also...

• Zyflo CR Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Zyflo CR Consumer Information (Cerner Multum)
• Zyflo CR Advanced Consumer Information (Micromedex)
• Zileuton Consumer Information (Wolters Kluwer)
• Zileuton Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Zileuton Consumer Information (Cerner Multum)
• Zileuton Advanced Consumer Information (Micromedex)
• Zileuton AHFS DI Monographs (ASHP)